Abstract: Immunotherapy represents the third revolution in the pharmacological treatment of tumors and has demonstrated considerable efficacy in the management of malignant solid tumors, including melanoma and lung cancer. In contrast, breast cancer is frequently categorized as a 'cold tumor' due to its limited immunogenicity and immunoreactivity, which hinder both research progress and clinical outcomes in immunotherapy. Consequently, only a small proportion of patients derive benefits from immunotherapeutic interventions, and the development of drug resistance remains a concern. This necessitates the exploration of novel strategies aimed at converting immunologically inert ‘cold tumors’ into immunologically active ‘hot tumors’, thereby expanding the benefit population of breast cancer immunotherapy. Based on the formation mechanism of ‘cold tumors’, this article reviews the new strategies to transform breast cancer from ‘cold’ to ‘hot’, including enhancing the expression of tumor antigens, promoting immune infiltration, and reversing immune cell suppression.